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Abstract
Background: To prevent debilitating and irreversible joint damage, rheumatoid arthritis (RA) is often treated with
tumor necrosis factor inhibitor (TNFi), but many patients do not respond to this costly therapy. Few predictors for
response are known, and it has been proposed that genetic factors which influence the development of RA may
also influence disease severity and response to therapy. Several previous studies have attempted to confirm this but
results remain inconclusive. We expand on previous studies by including more RA risk alleles, and maximize power
by combining them into a genetic risk score.
Method: We linked genotyped RA patients from the Epidemiological Investigation of Rheumatoid Arthritis study
to the Swedish Rheumatology Quality Register, identifying patients who started a TNFi as their first biological
disease-modifying anti-rheumatic drug, with a return visit within 2–8 months after treatment start (N = 867). We
calculated risk scores from 76 established RA risk SNPs, and four HLA-DRB1 amino acid positions, and tested
whether risk scores or individual genetic risk factors could predict the European League Against Rheumatism
(EULAR) response.
Results: We found no association between any of the risk scores or HLA-DRB1 haplotypes and EULAR response,
neither overall nor stratified by anti-citrullinated protein/peptide antibody (ACPA) status. When evaluating each of
the 76 SNPs, we found that the number of SNPs presenting significant associations was not higher than expected
by chance (5/76 SNPs had p < 0.05 in ACPA-positive RA, 4/76 in ACPA-negative RA).
Conclusion: Overall, known RA risk SNPs do not predict response to TNFi, either individually or when combined
into a risk score. This does not support the hypothesis that genes influencing RA onset would also influence its
prognosis and treatment response.
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Background
Tumor necrosis factor inhibitor (TNFi) therapy repre-
sents an important breakthrough in the treatment of the
chronic inflammatory joint disease rheumatoid arthritis
(RA). Although the therapeutic utility of TNFi is well
documented, the drugs are costly and patients display
substantial heterogeneity in treatment response: approxi-
mately 30% of patients discontinue therapy in the first
year, a decision often made due to lack of effect or ad-
verse events [1].
In order to personalize treatment, substantial efforts
have been made to identify factors predicting response
to TNFi. Environmental or clinical factors such as
smoking, gender, age, baseline disability, or presence of
autoantibodies account for only a small proportion of
the variability in patient response [2, 3]. Unfortunately,
genome-wide association studies (GWASs) have so far
not revealed any clear evidence of predictive genetic
markers, except for a large collection of nominally sig-
nificant markers [4–8], or a few markers which, despite
having approached acceptable levels of significance, are
too weak to inform any clinical decisions (such as
rs6427528 on CD84 with p = 8 × 10–8 in the etanercept
subsets of patients) [9].
Before the advent of GWASs, studies of treatment
response commonly focused on individual candidate
markers. This remains a viable strategy for conserving
power by reducing the number of simultaneous tests, if
good candidates can be found. Candidate genes in this
context have mainly come in two types: those involved
in TNF metabolism or mechanistic pathways, and those
associated with the onset of RA. Several investigations
with limited samples (less than 130 subjects) have been
conducted for the –308G >A polymorphism in the TNF
gene [10–18], and found that the GG genotype is associ-
ated with a better response to TNFi treatment [11, 16–18].
This finding, however, was neither supported by a follow-
ing study with a larger sample [19] nor replicated in subse-
quent genome-wide interrogations [4–7, 9].
Several studies have focused instead on individual
genes known to be associated with risk for RA, including
HLA-DRB1, PTPN22, IL, and FCGR, but no statistically
significant associations were found [2, 19–22], except for
one study finding two copies of HLA-DRB1 shared epi-
tope (SE) significantly associated with improved ACR50
response [23] and a recent study investigating amino
acid positions, rather than the SNPs per se, finding that
valine in amino acid position 11 in HLA-DRB1 (which is
outside the well-described SE positions) was associated
with radiological progression and response to TNFi [24].
GWASs have provided researchers with an expanded
list of RA risk genes. In a study of the then 31 identified
RA risk loci, only one SNP (rs10919563) on PTPRC/
CD45 was associated with European League Against
Rheumatism (EULAR) response and DAS28 changes
among TNFi starters, with reasonable replications and
acceptable sample sizes (ca. 1200 in each study) [25, 26].
With some possible exceptions, including the HLA re-
gion, this observation may suggest that most alleles con-
tributing to the development of RA do not influence
treatment response when the disease has been estab-
lished, and would be in line with the finding that a fam-
ily history of RA (a proxy of genetic liability to develop
RA) does not predict RA TNFi treatment response [27].
It could also be argued, however, that previous studies
were underpowered, and only focused on a subset of the
now identified genetic markers for RA.
We hypothesized that many alleles associated with the
development of RA are also important in predicting TNFi
response, albeit with small individual effects, and that the
previous failure to show this was due to lack of power. To
extend previous research, we included more RA risk alleles
and maximized power by combining these multiple poly-
morphisms into a single parameter—a genetic risk score.
We analyzed these genetic markers (all currently known
RA risk SNPs tagged by the Immunochip platform, and
genome-wide SNPs) and several HLA-DRB1 amino acids
(positions 11, 13, 71, and 74, and haplotypes defined by
these positions), grouped into scores as well as individually,
to evaluate how well they predict response to TNFi therapy
among patients with RA who used TNFi as their first bio-
logical disease-modifying anti-rheumatic drug (bDMARD).
Methods
We performed a cohort study in prospectively recorded
data by linking all participants in the Epidemiological
Investigation of Rheumatoid Arthritis (EIRA) incident
case–control study, who had been genotyped with the
Immunochip array, to the Swedish Rheumatology Quality
Register (SRQ), identifying patients starting TNFi therapy
as their first bDMARD and their response to this
treatment.
Epidemiological Investigation of Rheumatoid Arthritis
EIRA is a population-based case–control study initiated in
1996. Cases were recruited from all rheumatology pro-
viders within defined areas in Sweden, within 1 year of
symptom onset and initial visit to a rheumatologist. At
baseline, participants completed a self-administrated
questionnaire and provided blood samples for serologic
(anti-citrullinated protein/peptide antibodies (ACPA)) and
genetic examinations. A total of 5043 EIRA subjects (all
were recruited until 2009) were available on Immunochip
genotypes; after quality control, 4830 were eligible for
amino acid imputation. Imputation on amino acid posi-
tions 11, 13, 71, and 74 as well as the haplotypes based on
the four positions was finally successfully performed for
4726 participants (2785 patients and 1941 controls). We
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subsequently linked the EIRA patients with the SRQ to
further identify the target patient population of the
current study. All participants consented to be involved in
the study.
Swedish Rheumatology Quality Register
The SRQ is a profession-driven, web-based national
quality register engaging both patients and rheumatolo-
gists. This clinical register records longitudinal data en-
tered by the patient and the treating rheumatologist at
each visit. The nationwide coverage is good for patients
with newly diagnosed RA (about 80%), and is excellent
for RA patients treated with bDMARDs (about 90%). Of
the aforementioned 2785 EIRA patients with genetic in-
formation, 2576 were registered in the SRQ (92%); 895
were registered as starting any of the five TNFi agents
(etanercept, infliximab, adalimumab, certolizumab pegol,
and golimumab) as their first bDMARD. Finally, a total
of 867 subjects (653 ACPA-positive patients and 165
ACPA-negative patients) who had a valid visit registered
in the SRQ within 7 days of starting therapy were in-
cluded in the current study.
Exposures
We collected genetic information on the target patient
population in four forms. First, we identified RA patients
with the classical HLA-DRB1 SE, genotyped as described
previously [28]. Briefly, carriers of any of the HLA-
DRB1*01 (but not HLA-DRB1*0103), HLA-DRB1*04
(HLA-DRB1*0401, HLA-DRB1*0404, HLA-DRB1*0408),
and HLA-DRB1*10 alleles were defined as exposed; car-
riers of none of these alleles were defined as unexposed.
Second, we collected data on 76 RA risk SNPs as de-
scribed previously (Additional file 1: Table S1) [29]. Briefly,
based on the results of a meta-analysis of Immunochip
data for 11,475 cases and 15,870 controls of European
ancestry (which identified 46 RA risk SNPs), as well as a
trans-ethnic meta-GWAS of 29,880 cases and 73,758 con-
trols of European and Asian ancestry (which provided an
additional 49 RA risk SNPs/loci), we managed to obtain
data using our Immunochip material for all 46 SNPs from
the first study, and an additional 14 SNPs from the second
study; of the remaining 35 SNPs in the second study,
proxy SNPs with r2 > 0.6 were identified on 16 of them,
resulting in a total of 76 SNPs. We constructed a weighted
genetic risk score (GRS) by summing the alleles for each
individual, weighted by the logarithm of the published
odds ratio (OR) in the corresponding meta-GWAS, ac-




lnORSNPið Þ  CopySNPi
Third, in addition to the 76 RA risk SNPs, we further
made use of the whole Immunochip and calculated a
series of GRSs based on genome-wide association with
being an RA patient, estimated in the full EIRA material.
Those GRSs included SNPs with decreasing magnitudes
of effects—from the most stringent RA associations
(genome-wide significance), to the moderate associations
(e.g., p < 0.0005, p < 0.005, p < 0.05), to the least associ-
ated (all Immunochip markers)—and were weighted by
the logarithm of ORs derived from the corresponding
association analysis.
Finally, the four amino acid positions 11 (six polymor-
phisms), 13 (six polymorphisms), 71 (four polymorphisms),
and 74 (five polymorphisms) at HLA-DRB1, as well as the
haplotypes defined by those four positions, were imputed
as described previously (Additional file 2: Table S2) [30].
Briefly, the dosages of HLA amino acids were imputed
from the Immunochip data with a publicly released
reference panel generate by the Type 1 Diabetes Genetics
Consortium using SNP2HLA software [31]. Long-range
haplotypes across the MHC were obtained, which were
used to extract the corresponding haplotypes and amino
acid residues. We calculated the GRS for amino acid posi-
tions by summing up the dosages of residues for each indi-
vidual (each person could have two residues at each of the
four positions), weighted by the logarithm of its reported
association to develop RA (measured with the OR); simi-
larly, we calculated the GRS for haplotypes by weighting
each haplotype based on its reported OR [32], according to
the following equations:
GRSAA position ið Þ ¼
Xno: residues in position ið Þ
n¼1
lnORresidue in position ið Þ
 





  Copyhaplotype ið Þ
Outcomes
We collected the clinical characteristics for all of the eli-
gible RA patients at treatment start and an evaluation
visit, defined as a visit within 2–8 months after starting
therapy, closest to 5 months if patients had multiple
follow-up visits with valid DAS28 data. Disease activity
was measured with the DAS28, visual analog scale
(VAS) pain, Health Assessment Questionnaire (HAQ),
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), swollen joint count (SJC), tender joint count
(TJC), and VAS global health. We adopted two main
outcomes based on these measurements: EULAR re-
sponse, categorized as good/moderate vs none; and
changes in the disease activity measures, calculated by
subtracting the baseline values from the values at the
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evaluation visit, used in a continuous fashion (e.g.,
ΔDAS28, ΔCRP, etc.). In addition, to test the validity of
GRS, we also estimated how the distribution of the GRS
differed by RA status (RA vs controls).
Analysis
We analyzed the GRS of SNPs, amino acids, and haplo-
types, both as linear covariates (continuous) and categor-
ical covariates (divided into four categories according to
quartiles among controls). We also directly assessed indi-
vidual prediction from each SNP, amino acid, and haplo-
type (i.e., in its original format: 0/1/2 copies). We assessed
the association between achieving good/moderate vs no
EULAR response and GRS through logistic regressions.
We evaluated the association between the changes of
disease activity and GRS using R-square (R2) values from
linear regressions, given that delta values are virtually
normally distributed even without transformation. Two
post-hoc sensitivity analyses were made, where the main
analysis (categorical GRS as predictor of EULAR re-
sponse) was made first excluding etanercept to assess
whether the prediction was different when focusing on
monoclonal antibody therapies, and second restricting the
time window for the evaluation visit to 2–5 months
(60–150 days) to assess whether the broad time window
masked a specific association to response at that time
point. Finally, to illustrate the validity of the RA GRS in
this dataset, its association with RA risk (comparing the
RA cases with controls) was estimated by logistic regres-
sions. All analyses were performed by adjusting for age,
gender, and five principal components (PCs, to correct for
population stratification [33]) as well as stratified by
ACPA status.
Results
Clinical presentations of RA patients
Among the 867 RA patients who started TNFi as their
first bDMARD, 75% were ACPA-positive and 74% were
females. At the start of TNFi treatment, we identified
comparable clinical presentations between the two sub-
sets, except for a lower ESR (24.2 vs 29.0, p = 0.0068)
and a slightly higher TJC (8.9 vs 7.5, p = 0.0074) among
ACPA-negative patients. At follow-up, the improvement
in ACPA-positive patients and ACPA-negative patients
was similar for all outcome measures (Table 1).
GRS and RA risk
We found that not all of the GRSs followed normal
distributions—the risk score on position 11 was slightly
skewed, and on position 13 was collapsed into three
levels (Additional file 3: Table S3)—indicating a need to
analyze the amino acids individually. We examined the
associations between GRS and RA risk. As expected,
both the linear and categorical GRS only consistently
increased ACPA-positive RA risk but not ACPA-negative
RA risk (Table 2 and Additional file 4: Table S4).
GRS and TNFi treatment response
In contrast, we found no association between GRS (either
from the 76 SNPs, the four amino acids, or the haplotypes)
and good/moderate EULAR response in RA overall or in
ACPA-positive RA. Neither did the primary RA genetic
risk factor, SE, predict EULAR response (Table 3). Post-hoc
sensitivity analysis showed virtually identical results when
excluding etanercept (Additional file 5: Table S5). Post-hoc
sensitivity analysis restricting the evaluation time window
to months 2–5 did not find an association with the SNP-
based or haplotype-based GRS, but did find a borderline
significant reduced EULAR response associated with SE
Table 1 Clinical characteristics at start of TNFi treatment and
changes of outcome measures at follow-up visit (2–8 months)







Number of observations 867 653 165
Age, mean 51.2 51.3 51.5
Female (%) 74.1 72.1 79.2
Baseline values, mean
DAS28 5.0 5.0 5.0
CRP 21.0 21.9 19.1
ESR 27.9 29 24.2
SJC 7.8 7.8 8.1
TJC 7.8 7.5 8.9
VAS global health 54.1 53.8 54.5
VAS pain 53.5 53.4 53.5
HAQ 1.0 1.0 1.0
Changes from baseline to follow-up visit, mean
ΔDAS28 –1.5 –1.5 –1.6
ΔCRP –10.2 –10.4 –9.3
ΔESR –9.2 –9.5 –8.2
ΔSJC –4.9 –4.8 –5.3
ΔTJC –4.3 –4.1 –4.9
ΔVAS global health –21.1 –21.7 –19.2
ΔVAS pain –21.6 –22.3 –19.7
ΔHAQ –0.3 –0.3 –0.3
EULAR response (%)
No 25.2 25.6 23.6
Moderate 31.4 30.6 33.1
Good 43.4 43.8 43.3
ACPA anti-citrullinated protein/peptide antibodies, DAS28 disease activity score
28, CRP C-reactive protein, ESR erythrocyte sedimentation rate, RA rheumatoid
arthritis, SJC swollen joint count, TJC tender joint count, TNFi tumor necrosis
factor inhibitor, VAS visual analog scale, HAQ Health Assessment Questionnaire,
EULAR European League Against Rheumatism
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alleles (any SE allele OR = 0.69 (0.49–0.97), p = 0.0347, full
table in Additional file 6: Table S6). The second quartile of
GRS at amino acid position 13 appeared to be significantly
associated with improved EULAR response in ACPA-
negative RA, possibly due to low numbers in this stratum
(Additional file 7: Table S7). We then evaluated each of the
76 SNPs, each of the residues at the amino acid positions,
and each of the haplotypes associated with EULAR response
separately. The number of SNPs presenting significant
associations was not higher than expected by chance
(5/76 SNPs had p < 0.05 in ACPA-positive RA, 4/76 in
ACPA-negative RA) (Additional file 8: Table S8 and
Additional file 9: Figure S1). Similarly, despite the border-
line significance displayed by some residues in ACPA-
positive RA (glycine at position 11, serine and tyrosine at
position 13) and in ACPA-negative RA (proline at position
11, arginine at position 13), none survived multiple testing
corrections (Additional file 10: Table S9, 21 tests per-
formed). In addition, none of the haplotypes, either based
on four amino acids (11/13/71/74) or on three amino
acids (11/71/74, 11 and 13 are in high LD), were signifi-
cantly associated with good/moderate EULAR response in
RA overall or ACPA-positive RA, except for a few suggest-
ive significances in ACPA-negative RA (Table 4). We add-
itionally performed the haplotype analyses among patients
with high disease activity (baseline DAS28 > 5.1) but did
not identify any significant associations (Additional file 11:
Table S10). Furthermore, the sensitive analysis comparing
patients with good EULAR response with those with no
response (good vs no) did not reveal further evidence of
associations (Additional file 12: Table S11).
We further evaluated the performance of GRS and SE in
the changes of disease activity measures. As shown in
Table 5 and Additional file 13: Table S12, the only consist-
ent association with nominal significance lay in ΔHAQ in
ACPA-positive RA, where the GRS together with SE ex-
plained approximately 5% of variance (range: 3.4–5.4%),
although this significance would not withstand correction
for the number of tests (eight tests performed per amino
acid position). Moreover, amino acid positions 11 and 13
appeared to explain a moderate proportion of variance for
ΔESR (ca. 11%) in ACPA-negative RA, but this was not
significant after corrections for multiple tests (eight tests
performed per amino acid position). In addition, we found
no evidence supporting significant associations (that with-
stood multiple corrections) between GRS (composed of
76 SNPs) and any of the baseline clinical characteristics
(Additional file 14: Table S13).
Genome-wide polygenic risk score
The null findings already presented included markers
that were RA risk SNPs achieving genome-wide signifi-
cance in previous studies, and weaker RA risk alleles
remain to be identified, which may have an effect on
treatment response. Several lines of evidence have dem-
onstrated that currently known RA susceptibility loci
only account for a small proportion of ACPA-positive
RA heritability, even less in ACPA-negative RA; and that
by including additional common SNPs, the proportion
of RA genetic liability could be explained to a larger ex-
tent [34]. We hypothesized that the R2 estimates would
be improved by incorporating extra SNPs. We therefore
calculated several GRSs including SNPs with different
magnitudes of association to RA, demonstrated their
Table 2 Associations between genetic risk scores and overall
RA risk, as well as ACPA-positive and ACPA-negative RA risk
GRS Overall RA ACPA-positive RA ACPA-negative RA
GRS76SNP
Linear 2.03 (1.85–2.23) 2.44 (2.19–2.72) 1.21 (1.03–1.44)
Q1 Reference Reference Reference
Q2 vs Q1 1.40 (1.02–1.93) 1.57 (1.04–2.38) 1.25 (0.77–2.05)
Q3 vs Q1 2.39 (1.78–3.22) 3.43 (2.36–5.00) 1.33 (0.81–2.16)
Q4 vs Q1 4.99 (3.77–6.61) 8.01 (5.60–11.45) 1.49 (0.92–2.42)
GRSHaplotype
Linear 2.13 (1.94–2.34) 2.57 (2.30–2.87) 1.19 (1.00–1.42)
Q1 Reference Reference Reference
Q2 vs Q1 1.68 (1.21–2.34) 2.70 (1.69–4.33) 1.19 (0.74–1.91)
Q3 vs Q1 3.64 (2.72–4.88) 8.11 (5.34–12.31) 1.06 (0.65–1.71)
Q4 vs Q1 7.08 (5.24–9.57) 16.11 (10.51–24.69) 1.47 (0.89–2.41)
Data presented as odds ratio (95% confidence interval)
ACPA anti-citrullinated protein/peptide antibodies, GRS genetic risk score,
RA rheumatoid arthritis, Q, quartile
Table 3 Associations between genetic risk scores and TNFi
treatment response (achieving good/moderate EULAR response
vs no) in overall RA, as well as in ACPA-positive RA and
ACPA-negative RA
GRS Overall RA ACPA-positive RA ACPA-negative RA
GRS76SNPs
Linear 0.96 (0.81–1.14) 1.00 (0.82–1.22) 0.89 (0.56–1.42)
Q1 Reference Reference Reference
Q2 vs Q1 0.68 (0.31–1.50) 1.00 (0.36–2.81) 0.66 (0.17–2.54)
Q3 vs Q1 0.77 (0.37–1.60) 1.07 (0.42–2.71) 0.60 (0.15–2.36)
Q4 vs Q1 0.79 (0.39–1.57) 1.06 (0.44–2.55) 0.95 (0.23–3.93)
GRSHaplotype
Linear 0.92 (0.77–1.12) 0.96 (0.76–1.20) 1.30 (0.80–2.12)
Q1 Reference Reference Reference
Q2 vs Q1 1.15 (0.51–2.61) 0.76 (0.22–2.65) 2.35 (0.67–8.20)
Q3 vs Q1 1.05 (0.52–2.12) 0.89 (0.30–2.65) 2.19 (0.58–8.30)
Q4 vs Q1 0.99 (0.48–2.02) 0.84 (0.27–2.54) 3.53 (0.88–14.22)
Any SE 0.79 (0.59–1.06) 0.84 (0.59–1.20) 1.07 (0.53–2.17)
Data presented as odds ratio (95% confidence interval)
ACPA anti-citrullinated protein/peptide antibodies, GRS genetic risk score,
RA rheumatoid arthritis, Q quartile, SE shard epitope, TNFi tumor necrosis
factor inhibitor, EULAR European League Against Rheumatism
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predictive capacity with regards to RA risk, and then
assessed the association with response to TNFi using
these scores; the results are plotted in Fig. 1. We found
no visible trends that R2 would increase as numbers of
incorporated markers increased.
Discussion
By linking clinical data from the Swedish Rheumatology
Register to genetic data from the EIRA study, we evaluated
whether known RA susceptibility genes, HLA-DRB1
amino acids, and haplotypes, either individually or inte-
grated into a risk score, predicted treatment response to
TNFi therapy. Although all were strong predictors of RA, a
high genetic risk score was not associated with good
EULAR response in either overall RA or stratified by
ACPA status.
Our results are in line with, but also extend, the pre-
vious GWAS and candidate gene approach findings, and
Table 4 Associations between individual HLA-DRB1 haplotype and achieving good/moderate EULAR response, in overall RA, as well
as in ACPA-positive RA and ACPA-negative RA
Haplotype Prevalence (%) Overall RA ACPA-positive RA ACPA-negative RA
PRAA 10.2 Reference Reference Reference
DFRE 1.7 1.60 (0.51–5.03) 1.60 (0.48–5.34) NA
GYRQ 4.8 0.59 (0.29–1.19) 0.64 (0.28–1.47) 0.18 (0.03–1.28)
LFEA 0.4 0.23 (0.04–1.55) NA NA
LFRA 14.9 0.89 (0.51–1.56) 0.93 (0.49–1.79) 0.33 (0.06–1.88)
PRRA 0.8 0.89 (0.20–3.94) 2.15 (0.23–20.28) NA
SGRA 1.7 0.72 (0.26–1.96) 0.81 (0.27–2.47) 0.28 (0.01–5.30)
SGRL 2.9 1.00 (0.41–2.43) 1.23 (0.37–4.10) 0.14 (0.02–0.95)
SSEA 5.4 0.92 (0.45–1.86) 1.31 (0.53–3.28) 0.12 (0.02–0.73)
SSKA 0.7 2.49 (0.29–21.30) NA 0.12 (0.01–2.59)
SSKR 9.3 0.99 (0.47–2.10) 1.23 (0.51–2.99) 0.04 (0.00–0.39)
SSRA 3.6 1.98 (0.78–5.00) 2.43 (0.81–7.32) 0.55 (0.06–5.03)
SSRE 1.1 1.59 (0.32–7.82) 2.58 (0.30–22.14) 0.10 (0.00–2.41)
VFRA 2.1 0.52 (0.21–1.24) 0.60 (0.22–1.63) 0.17 (0.01–2.84)
VHEA 0.3 1.14 (0.11–12.24) 1.58 (0.14–17.89) NA
VHKA 27.0 0.78 (0.46–1.32) 1.08 (0.59–1.97) 0.16 (0.03–0.93)
VHRA 11.9 1.10 (0.62–1.97) 1.20 (0.62–2.33) 0.93 (0.11–8.00)
VHRE 1.3 1.03 (0.31–3.43) 2.11 (0.43–10.35) 0.03 (0.00–0.55)
PAA 10.2 Reference Reference Reference
DRE 1.7 1.59 (0.51–5.01) 1.56 (0.47–5.20) NA
GRQ 4.8 0.59 (0.29–1.19) 0.63 (0.27–1.45) 0.19 (0.03–1.33)
LEA 0.4 0.23 (0.03–1.50) NA NA
LRA 14.9 0.89 (0.51–1.55) 0.93 (0.49–1.77) 0.34 (0.06–1.92)
PRA 0.8 0.90 (0.20–3.98) 2.11 (0.22–19.84) NA
SEA 5.4 0.95 (0.47–1.91) 1.36 (0.55–3.39) 0.13 (0.02–0.75)
SKA 0.7 2.62 (0.31–22.35) NA 0.13 (0.01–2.73)
SKR 9.3 1.01 (0.48–2.13) 1.26 (0.52–3.05) 0.05 (0.00–0.43)
SRA 5.3 1.34 (0.64–2.79) 1.51 (0.65–3.52) 0.48 (0.06–3.63)
SRE 1.1 1.52 (0.31–7.42) 2.47 (0.29–21.15) 0.10 (0.00–2.51)
SRL 2.9 0.94 (0.39–2.27) 1.20 (0.36–3.98) 0.13 (0.02–0.92)
VEA 0.3 1.15 (0.11–12.39) 1.56 (0.14–17.60) NA
VKA 27.0 0.77 (0.46–1.30) 1.06 (0.58–1.94) 0.15 (0.03–0.91)
VRA 14.0 0.95 (0.55–1.64) 1.04 (0.55–1.94) 0.64 (0.09–4.31)
VRE 1.3 1.03 (0.31–3.44) 2.08 (0.42–10.27) 0.04 (0.00–0.66)
ACPA anti-citrullinated protein/peptide antibodies, RA rheumatoid arthritis, EULAR European League Against Rheumatism
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indicate that although treatment response in RA has
been reported to be somewhat heritable [35], the genetic
variants that influence disease onset do not necessarily
influence TNFi treatment response to the same extent.
This is also supported by a recent study showing that
family history of RA did not predict RA TNFi treatment
response [27], although this on its own could have been
due to the information on genetic risk contained in a
family history being too slight among patients who are
all at high genetic risk, as evident from them having
already developed the disease.
The SNP that was found to be significantly associated
with both RA risk and TNFi treatment response
(PTPRC/CD45 rs10919563 at chromosome 1) in a previ-
ous larger sample [25] could unfortunately not be repli-
cated in our study because of lack of proxies (the closest
possible SNP to the PTPRC region available in our
material is 100 kbp distant). Even though weak yet nom-
inally significant associations were indeed identified on a
handful of individual genetic markers in the current
study, they were neither strong enough to withstand
correction for multiple testing nor close enough to be
clinically informative. Unfortunately, this has also been
the case in previous studies. For example, the first TNFi
treatment response GWAS performed in 89 RA patients
by Liu et al. [5] provided a reference list of 16 candidate
SNPs with suggestive significance; none was replicated
in a subsequent separate study with slightly larger sam-
ples (n = 151) [36]. Plant et al. [6] performed a multi-
stage GWAS in 1285 RA patients and found seven
genetic loci that might influence treatment response; none
survived the two additional replication attempts [4, 7].
Similarly, the majority of the markers identified by
Table 5 Variance in disease activity changes by genetic risk




Overall RA ACPA-positive RA ACPA-negative RA
R2 p R2 p R2 p
GRS76SNPs
ΔDAS28 0.016747 0.14 0.016816 0.32 0.031191 0.77
ΔCRP 0.008274 0.63 0.007312 0.84 0.098850 0.08
ΔESR 0.005006 0.88 0.003705 0.98 0.063739 0.32
ΔSJC 0.003122 0.96 0.005690 0.91 0.052132 0.44
ΔTJC 0.009859 0.49 0.009595 0.71 0.032586 0.75
ΔVAS global 0.007589 0.67 0.007651 0.82 0.024461 0.87
ΔVAS pain 0.012959 0.30 0.013727 0.48 0.027700 0.82
ΔHAQ 0.019911 0.10 0.034497 0.03 0.019770 0.93
GRS76SNPs + GRSAAs + SE
ΔDAS28 0.025706 0.50 0.034035 0.52 0.107155 0.70
ΔCRP 0.016461 0.89 0.014948 0.98 0.159459 0.28
ΔESR 0.017487 0.87 0.016454 0.98 0.104736 0.74
ΔSJC 0.007558 1.00 0.017127 0.96 0.136713 0.42
ΔTJC 0.020931 0.71 0.020560 0.91 0.095691 0.79
ΔVAS global 0.019875 0.76 0.021503 0.89 0.131984 0.47
ΔVAS pain 0.025917 0.50 0.030989 0.63 0.140222 0.39
ΔHAQ 0.029739 0.41 0.054253 0.12 0.115604 0.68
AA amino acid, ACPA anti-citrullinated protein/peptide antibodies, GRS genetic
risk score, RA rheumatoid arthritis, SE shared epitope, DAS28 disease activity
score 28, CRP C-reactive protein, ESR erythrocyte sedimentation rate,
SJC swollen joint count, TJC tender joint count, VAS visual analog scale,
HAQ Health Assessment Questionnaire
Fig. 1 Variance in disease activity change explained by GRS calculated based on polygenic models in overall RA. x axis, p-value thresholds of
SNPs included to calculate a genetic risk score. y axis, R2 values calculated from the polygenic model. Eight different clinical measures are examined: ΔCRP,
ΔDAS28, ΔHAQ, ΔTJC, ΔVAS-global, ΔVAS-pain, ΔESR, ΔSJC. Dots map the R2 value calculated from the polygenic model, modeling clinical measures as
outcomes and the corresponding genetic risk score as the independent variable. DAS28 disease activity score 28, CRP C-reactive protein, ESR erythrocyte
sedimentation rate, SJC swollen joint count, TJC tender joint count, VAS visual analog scale, HAQ Health Assessment Questionnaire
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Krintel et al. [4] in 196 Danish RA patients did not with-
stand replication in another 315 Spanish subjects [37].
However, one SNP (rs3794271) at PDE3A-SLCO1C1
reached genome-wide significance in the meta-analysis
combining the Danish and Spanish cohorts. Further inves-
tigations are needed for this pharmacogenetics biomarker
of interest. GWASs performed after Liu et al. attempted
to both identify new predictors and replicate previous
findings, neither of which succeeded. This may be due to
the small sample size for GWASs, where often 2–5
million SNPs were analyzed with an average sample size
less than 1000. We attempted to increase power by com-
bining many SNPs into a single score, yet still failed to re-
veal any significant associations. We considered that there
may still be a genetic overlap among the as yet unidenti-
fied RA alleles, but found no evidence for this because we
did not observe any apparent increment of variance ex-
plained in any of the disease activity measures when a
genome-wide polygenic risk score model was performed.
This might indicate that RA risk alleles do not necessarily
have an effect on TNFi treatment, despite most of the
current treatment target genes/pathways being involved in
general inflammatory response; it may be reasonable to
expect more and different biological pathways via which
TNFi exerts its effect. In light of the limited statistical
power in the current study, however, RA risk SNPs with
modest effects in TNFi treatment response cannot be
ruled out. One nominally significant finding may deserve
mention: rs629326 (located 23.61 kb 5′ of TAGAP, in-
volved in T-cell activation) was fairly strongly associated
with EULAR response in our material, with OR = 0.31
(0.15–0.62), and FDR-adjusted (for 76 tests) p = 0.08.
Further, the HLA-DRB1 SE alleles were associated with
reduced EULAR response when restricting the time
window to 2–5 months (OR = 0.69 (0.49–0.97), unadjusted
p = 0.0347), although this was a post-hoc analysis and
the p value would not remain significant after adjusting
for multiple testing. Interestingly, specific HLA-DRB1
amino acids have been associated previously with TNFi
treatment response, where valine at amino acid position
11 was reported to be associated with a smaller change in
Larsen score, and improved EULAR response [24]. We
unfortunately lacked data on joint erosions. Our results
for treatment response, however, did not immediately
support the finding that the valine-containing VKA
haplotype was associated with a good EULAR response
(OR in [24] = 1.23 (1.06–1.43)), while the OR was 1.06
(0.58–1.94) for our data among ACPA-positive RA pa-
tients. The confidence intervals overlap greatly, and we
are thus unable to either refute or confirm this previous
finding. We did find a nominally significant association of
residue serine (OR = 1.96 (1.14–3.37)) at position 13 and
tightly linked with valine at position 11. This should be
interpreted with caution, however, because it was not
statistically significant after correcting for the multiplicity
of tests. When the haplotype analyses were restricted to pa-
tients with high disease activity RA (baseline DAS > 5.1), to
maximize comparability with the UK study, the associ-
ation with valine further diminished (Additional file 11:
Table S10).
When addressing continuous measures of treatment
response, interestingly, all of the risk scores seemed to
consistently explain a small yet significant proportion
(5%) of the variance in HAQ changes in ACPA-positive
RA. The clinical value of such results warrants further
confirmation. It has been suggested that the modest
influence of genetic effects on treatment response is due
to the “composite” traits of the DAS28 score that most
outcomes are based upon, and which relies on informa-
tion from both subjective and objective measures [26];
and that using a well-defined phenotype could aid in dis-
closing the true genetic effects [26]. We examined each
component of the DAS28 without seeing any remarkable
associations, except for a small proportion of variance in
ESR change explained by amino acid risk score in
ACPA-negative RA, which suffered markedly from lim-
ited power.
One strength of the current study is the accuracy of
both exposures and outcomes. The genetic data were
genotyped and quality controlled, and the amino acid
data, although imputed, presented a high concordance
rate as compared with true genotyping data (a 97.3%
concordance rate for two-digit SE and 95.0% for four-
digit SE) [30]. We used clinically relevant outcome
measures recommended by the European guidelines
collected as part of clinical practice in an unselected
manner. Because no environmental confounders could
in practice influence the genetic markers, we performed
the analyses without including adjustment for many co-
variates to preserve power. One limitation is insufficient
power, which could cause false positive findings, and we
consider the overall lack of association to be the main
conclusion of this study. Another weakness of this study
is the time point at which clinical response to TNFi
therapy is determined. In a highly heterogeneous disease
like RA, time of clinical assessment is crucial and can
substantially modify response classification. However,
our register-based data could not provide evaluation at
time points as exact as those usually obtained in con-
trolled trials, but rather in a time window, reflecting the
Swedish clinical practice. We performed a post-hoc
sensitive analysis restricting the time window for the
evaluation visit to 2–5 months, and the results remained
the same.
Conclusion
Our negative results imply that there is no strong evi-
dence supporting a significant role of RA risk genes in
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the response to TNFi treatment; and that none of the
SNPs, amino acids, or haplotypes examined in our study
seem to be meaningful individual predictors of TNFi
therapy, although weak associations cannot be ruled out.
Although this suggest that future studies of TNFi re-
sponse may want to focus on other genetic risk factors,
combining genetic information connected to RA onset
with clinical, nongenetic predictors, or perhaps their
interaction, may also potentially prove valuable.
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